Please Wait
Applying Filters...
menu
    • menu
    FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector 2025 highlights: FDA approves pill version of Novo’s Wegovy; BioMarin acquires Amicus for US$ 4.8 bn

    Stock Recap
    #PipelineProspector

    Menu

    Inclisiran

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 700,271Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    30/12/2025 ST Pharma
    South Korea
    		 Novartis Korea Co., Ltd. Su196-29-ND inclisiran sodium 2024-06-20 ST Pharm Co., Ltd. South Korea 171 Haean-ro, Danwon-gu, Ansan-si, Gyeonggi-do
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.